Table 1.
Characteristics of 5 randomized controlled trials evaluating transepithelial CXL versus epi-off CXL.
| Study* (Y) | ClinicalTrials.gov | Country | Follow-Up (Mo) | Treated Eyes (N) | Mean Age (Y) | Mean Baseline Kmax (D) | |||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Transepithelial CXL | Epi-Off CXL | Transepithelial CXL | Epi-Off CXL | Transepithelial CXL | Epi-Off CXL | ||||
|
| |||||||||
| Al Fayez16 (2015) | Not registered | Saudi Arabia | 36 | 34 | 36 | 24.8 | 24.1 | N/A | N/A |
| Bikbova18 (2016) | NCT02456961 | Russia | 24 | 76 | 73 | 28.0 | 30.0 | 48.28 | 48.83 |
| Lombardo19 (2017) | NCT02117999 | Italy | 12 | 22 | 12 | 31.0 | 29.4 | 54.7 | 54.7 |
| Rossi14 (2015) | Not registered | Italy | 12 | 10 | 10 | 28.0 | 30.4 | 52.41 | 51.64 |
| Rush17 (2017) | NCT01708538 | United States | 24 | 75 | 56 | 29.8 | 31.5 | 51.34 | 52.03 |
| Soeters15 (2015) | NCT02349165 | Netherlands | 12 | 35 | 26 | 26.91 | 25.85 | 56.4 | 57.8 |
| Stojanovic13 (2014) | NCT01181219 | Norway | 12 | 20 | 20 | 29.45 | 29.45 | 52.68 | 53.59 |
CXL = corneal crosslinking; epi-off = epithelium-off; Kmax = maximum keratometry; N/A = Not available
*
First author